National Institute of Diabetes and Digestive and Kidney Diseases Notice of Closed Meetings, 56206-56207 [2011-23228]
Download as PDF
<![CDATA[
56206
Federal Register / Vol. 76, No. 176 / Monday, September 12, 2011 / Notices
The
Agency requests nominations for
nonvoting industry representatives on
the Tobacco Products Scientific
Advisory Committee.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK4VPTVN1PROD with NOTICES
I. Tobacco Products Scientific Advisory
Committee
The Tobacco Products Scientific
Advisory Committee (the Committee)
advises the Commissioner of Food and
Drugs (the Commissioner) or designee in
discharging responsibilities as they
relate to the regulation of tobacco
products. The Committee reviews and
evaluates safety, dependence, and
health issues relating to tobacco
products and provides appropriate
advice, information, and
recommendations to the Commissioner.
The Committee includes three
nonvoting members who represent
industry interests. These members
include one representative of the
tobacco manufacturing industry, one
representative of the interests of tobacco
growers, and one representative of the
interests of the small business tobacco
manufacturing industry. The
representative of the interests of the
small business tobacco manufacturing
industry may be filled on a rotating,
sequential basis by representatives of
different small business tobacco
manufacturers based on areas of
expertise relevant to the topics being
considered by the Committee.
With this notice, nominations are
sought for the following positions: (1)
One representative of the interests of
tobacco growers, and an alternate to this
representative; (2) a pool of individuals,
with varying areas of expertise, to
represent the interests of the small
business tobacco manufacturing
industry on a rotating, sequential basis;
and (3) an individual to serve as
alternate to the representative of the
tobacco manufacturing industry.
II. Selection Procedure
Any industry organization interested
in participating in the selection of
appropriate nonvoting member(s) to
represent industry interests should send
a letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
CONTACT and DATES). Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations,
and a list of all nominees along with
their current resumes. The letter will
also state that it is the responsibility of
the interested organizations to confer
with one another and to select a
candidate, within 60 days after the
receipt of the letter, to serve as the
VerDate Mar<15>2010
16:36 Sep 09, 2011
Jkt 223001
nonvoting member to represent industry
interests on the Committee. The
interested organizations are not bound
by the list of nominees in selecting a
candidate. However, if no individual is
selected within 60 days, the
Commissioner will select the nonvoting
member to represent the industry
interests.
III. Application Procedure
Individuals may self-nominate and/or
organizations may nominate one or
more individuals to serve as a nonvoting
industry representative (for the roles
specified in this document).
Nominations must include a current
resume or curriculum vitae of the
nominee including current business
address and/or home address, telephone
number, e-mail address if available, and
the role for which the individual is
being nominated. Nominations must
also acknowledge that the nominee is
aware of the nomination unless selfnominated. FDA will forward all
nominations to the organizations
expressing interest in participating in
the selection process for the committee.
(Persons who nominate themselves as
nonvoting industry representatives will
not participate in the selection process.)
FDA has a special interest in ensuring
that women, minority groups, and
individuals with physical disabilities
are adequately represented on its
advisory committees and, therefore,
encourages nominations for
appropriately qualified candidates from
these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: September 7, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–23185 Filed 9–9–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, ‘‘NIAID Contract Review
Meeting 2011’’.
Date: October 3, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Brandt R. Burgess, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
DHHS/NIH/NIAID, 6700B Rockledge Drive,
MSC 7616, Bethdesda, MD 20892–7616, (301)
451–2584, bburgess@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–23231 Filed 9–9–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; The NIDDK–KUH
Fellowship Review.
Date: October 6, 2011.
Time: 9 a.m. to 12 p.m.
E:\FR\FM\12SEN1.SGM
12SEN1
Federal Register / Vol. 76, No. 176 / Monday, September 12, 2011 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK DEM
Fellowship Review.
Date: October 12–13, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Carol J. Goter-Robinson,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 748, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791,
goterrobinsonc@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Special Emphasis Panel, NIDDK Ancillary
Studies.
Date: September 26, 2011.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call.)
Contact Person: Thomas A. Tatham, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452. (301) 594–3993.
tathamt@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2011–23228 Filed 9–9–11; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the public
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Commitee: National Institute of
Diabetes and Digestive and Kidney Diseases
16:36 Sep 09, 2011
Jkt 223001
[FR Doc. 2011–23227 Filed 9–9–11; 8:45 am]
Program, Division of Extramural Activities,
DHHS/NIH/NIAID, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892, 301–402–
9523, zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–23226 Filed 9–9–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2011 Funding
Opportunity
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of intent to award a
Single Source Grant to Link2Health
Solutions, Inc.
AGENCY:
BILLING CODE 4140–01–P
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) intends to award
approximately $2,100,000 (total costs)
for up to one year to Link2Health
Solutions, Inc. the current grantee for
the National Suicide Prevention
Lifeline. This is not a formal request for
applications. Assistance will be
provided only to Link2Health Solutions,
Inc based on the receipt of a satisfactory
application that is approved by an
independent review group.
Funding Opportunity Title: SM–11–
015.
SUMMARY:
National Institutes of Health
BILLING CODE 4140–01–P
VerDate Mar<15>2010
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
56207
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Allergy, Immunology,
and Transplantation Research Committee.
Date: October 18, 2011.
Time: 10 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Zhuqing Li, Ph.D.,
Scientific Review Officer, Scientific Review
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
Catalog Of Federal Domestic Assistance
(CFDA) Number: 93.243.
Authority: Section 501(d)(3) of the Public
Health Service Act, as amended.
Justification: Only an application
from Link2Health Solutions will be
considered for funding under this
announcement. One-year supplemental
funding has become available to assist
SAMHSA in responding to the growing
and pressing need to provide a Disaster
Distress Helpline for individuals
stressed by the aftermath of manmade
and/or natural disasters. It is considered
most cost-effective and efficient to
supplement the existing grantee for the
National Suicide Prevention Lifeline
and to build on the existing capacity
and infrastructure within its network of
crisis centers.
E:\FR\FM\12SEN1.SGM
12SEN1
]]>Agencies
[Federal Register Volume 76, Number 176 (Monday, September 12, 2011)]
[Notices]
[Pages 56206-56207]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-23228]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; The NIDDK-KUH Fellowship
Review.
Date: October 6, 2011.
Time: 9 a.m. to 12 p.m.
[[Page 56207]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Xiaodu Guo, MD, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 761,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; NIDDK DEM Fellowship
Review.
Date: October 12-13, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Carol J. Goter-Robinson, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 748, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7791, goterrobinsonc@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: September 6, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-23228 Filed 9-9-11; 8:45 am]
BILLING CODE 4140-01-P
